Ligand Pharma (LGND) introduces 2023 financial guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Ligand Provides Highlights from its Investor and Analyst Day Event
December 13, 2022 8:30 AM ESTExecutive Management Reviewed Business Model and Growth Drivers Following the Successful Spin-Off of OmniAb, Introduced 2023 Financial Guidance
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that at todays Investor and Analyst Day event its executive management provided an overview of Ligands corporate structure and business following the successful spin-off of its OmniAb antibody discovery business, reviewed Ligands recent progress and near-term partner milestones and provided an outlook for financial growth. Management also introduced 2023 financial guidance and discussed its capital deployment strategy. A webcast... More
